healthcare-thumbnail.png

Leukemia Market Research Report

Published: 2025 - January

Report Code: VMR-17540

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Leukemia Market Analysis 

The leukemia market refers to the sector dedicated to the treatment and management of leukemia, a type of cancer that affects blood and bone marrow. Leukemia is characterized by the uncontrolled growth of abnormal white blood cells. This market includes both acute and chronic leukemia subtypes, such as Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Chronic Myeloid Leukemia (CML).

Disruptive Impact and Opportunities:

The leukemia market is undergoing a transformative shift due to several advancements in targeted therapies and immunotherapies. New treatments, particularly novel biologics, are reshaping the treatment landscape, offering hope for patients with previously difficult-to-treat forms of leukemia. The development of drugs such as Bruton's Tyrosine Kinase (BTK) inhibitors, BCL-2 inhibitors, and CAR T-cell therapies has the potential to revolutionize patient outcomes by providing safer, more effective, and easier-to-administer treatment options. Additionally, new therapeutic combinations present significant market opportunities, catering to the growing demand for more efficient and individualized cancer care.

Leukemia Market Segmentation - Emerging Drugs

  • Pirtobrutinib

  • Cirmtuzumab

  • MS-553

  • NX-2127

  • NX-5948

  • Olaptesed pegol

  • Zanubrutinib

  • Ublituximab

  • LOXO305

Leukemia Market Segmentation - Marketed Drugs

  • Ibrutinib (Imbruvica), alone or with rituximab (Rituxan)

  • Zanubrutinib (Brukinsa)

  • Acalabrutinib (Calquence)

  • Venetoclax (Venclexta)

  • Venetoclax, Bendamustine, and rituximab

Key Companies:

  • Loxo Oncology

  • Oncternal Therapeutics

  • MingSight Pharmaceuticals

  • Nurix Therapeutics

  • Starton Therapeutics

  • TG Therapeutics

  • Bristol Myers Squibb

  • Novartis

  • Aprea Therapeutics

  • AstraZeneca

  • Genor Biopharma

  • Incyte Corporation

Leukemia Market Segmentation - By Type

·  Acute Leukemia

  • Acute Lymphoblastic Leukemia (ALL)

  • Acute Myeloid Leukemia (AML)

·  Chronic Leukemia

  • Chronic Lymphocytic Leukemia (CLL)

  • Chronic Myeloid Leukemia (CML)

·  Other Leukemia Types

  • Hairy Cell Leukemia (HCL)

  • Large Granular Lymphocytic Leukemia (LGL)

Leukemia Market Segmentation -  By Administration Type

·  Oral

  • Tablets

  • Capsules

·  Injectable

  • Intravenous (IV)

  • Subcutaneous (SC)

What’s in It for You?

  • Discover emerging trends and therapies disrupting the leukemia treatment landscape.

  • Identify key opportunities in the development of novel therapies, especially targeted and immunotherapies.

  • Explore market dynamics and competitive strategies employed by leading players.

  • Gain insights into ongoing clinical trials and drug pipeline advancements.

  • Understand the evolving treatment paradigms and the impact of innovative therapies on market growth.

  • Stay ahead of the curve with actionable intelligence on market shifts and potential challenges.

Leukemia Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Leukemia Market - Executive Summary                                           

               1.1. Introduction                             

               1.2. Objectives                 

               1.3. Key Findings                             

                              1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

                              1.3.2. Global Market Size 2022 & 2032: By Key Segment  

                              1.3.3. Key Investments & Startup Analysis             

               1.4. Research Methodology                        

                                            

2. Understanding the Disease                                   

               2.1. Disease Overview                   

               2.2. Classification                            

               2.3. Signs and Symptoms                             

               2.4. Risk Factors              

               2.5. Causes                       

               2.6. Disease Biology & Digital Innovations                            

               2.7. Stages & Staging System                     

               2.8. Diagnostic Algorithm                            

               2.9. Current Treatment Practices & Algorithm                     

               2.10. Current Standard of Care and Treatment Gaps                        

               2.11. Patient Demographics and Treatment Pathways                     

                                            

3. Guidelines                                    

                                            

4. Unmet Needs                                            

                                            

5. Epidemiology and Patient Population                                

               5.1. Epidemiology Key Findings                  

               5.2. Assumptions and Rationale: 10MM                

               5.3. Epidemiology Scenario: 10MM                         

               5.4. U.S. Epidemiology Scenario                

               5.5. EU-5 Epidemiology                 

                              5.5.1. U.K. Epidemiology Scenario            

                              5.5.2. Germany Epidemiology Scenario   

                              5.5.3. France Epidemiology Scenario       

                              5.5.4. Italy Epidemiology Scenario            

                              5.5.5. Spain Epidemiology Scenario          

               5.6. Japan Epidemiology Scenario                            

               5.7. China Epidemiology Scenario                            

               5.8. Australia Epidemiology Scenario                      

               5.9. India Epidemiology Scenario                             

                                            

6. Real-world Data & Real-world Evidence                                           

                                            

7. Drug Development Landscape                                            

               7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies                    

                              7.1.1. VANFLYTA (quizartinib)       

                                             7.1.1.1. Product Description

                                             7.1.1.2. Regulatory Milestones

                                             7.1.1.3. Other Developmental Activities

                                             7.1.1.4. Pivotal Clinical Trials

                                             7.1.1.5. Ongoing Current Pipeline Activity

                              7.1.2. ONUREG (azacitidine)        

                                             7.1.2.1. Product Description

                                             7.1.2.2. Regulatory Milestones

                                             7.1.2.3. Other Developmental Activities

                                             7.1.2.4. Pivotal Clinical Trials

                                             7.1.2.5. Ongoing Current Pipeline Activity

                              7.1.3. TIBSOVO 

                                             7.1.3.1. Product Description

                                             7.1.3.2. Regulatory Milestones

                                             7.1.3.3. Other Developmental Activities

                                             7.1.3.4. Pivotal Clinical Trials

                                             7.1.3.5. Ongoing Current Pipeline Activity

               7.2. Competitive Analysis and Differentiation                      

               7.3. Overview of Similar/Competing Drugs in Clinical Trials                           

               7.4. Future Trends and Emerging Drugs                 

                              7.4.1. Crenolanib             

                                             7.4.1.1. Product Description

                                             7.4.1.2. Clinical Development

                                             7.4.1.3. Safety and Efficacy

                              7.4.2. SLS009     

                                             7.4.2.1. Product Description

                                             7.4.2.2. Clinical Development

                                             7.4.2.3. Safety and Efficacy

                              7.4.3. Iomab-B  

                                             7.4.3.1. Product Description

                                             7.4.3.2. Clinical Development

                                             7.4.3.3. Safety and Efficacy

                              7.4.4. Azacitidine and cedazuridine (ASTX030)     

                                             7.4.4.1. Product Description

                                             7.4.4.2. Clinical Development

                                             7.4.4.3. Safety and Efficacy

                                            

8. Regulatory Strategy and Potential Challenges                                

               8.1. Regulatory Pathways in Key Markets                             

               8.2. Anticipated Regulatory Hurdles and Mitigation Strategies                     

               8.3. Case Studies in Oncology Drug Regulation                    

               8.4. Impact of Potential Changes to Regulatory Framework                          

                                            

9. Commercial Landscape                                          

               9.1. Market Size & Growth Rates                             

               9.2. Key Approvals & Anticipated Loss of Exclusivity                         

               9.3. PESTLE & Porter’s Five Forces Analysis                          

               9.4. Market Shares, Positioning/Ranking                

               9.5. Market Drivers                        

               9.6. Identification of Threats                      

               9.7. Digital Evolution in Commercialization                           

                                            

10. Market Segmentation                                           

               10.1. Market by Type                    

                              10.1.1. Acute Lymphocytic Leukemia       

                              10.1.2. Acute Myeloid Leukemia

                              10.1.3. Chronic Lymphocytic Leukemia   

                              10.1.4. Chronic Myeloid Leukemia           

                              10.1.5. Others   

               10.2. Market by Therapy Type                   

                              10.2.1. Surgery  

                              10.2.2. Chemotherapy   

                              10.2.3. Targeted Therapy             

                              10.2.4. Others   

                                            

11. Pricing, Reimbursement, and Access                              

               11.1. Competitive Pricing Analysis                           

               11.2. Reimbursement Landscape and Challenges               

               11.3. Strategies for Market Access and Equity                     

               11.4. Patient Spending/Expenditure Analysis                      

                                            

12. Future Trends, Disruptions, and Opportunities                                           

               12.1. Analysis of Emerging Trends                           

               12.2. Technological Impact                         

               12.3. Impact of Potential Market Disruptors                        

               12.4. Opportunities for Future Development and Expansion                         

               12.5. Considerations for Investment Opportunities                           

                                            

13. Global Market Dynamics                                     

               13.1. Regional Regulatory Disparities                      

               13.2. Cross-Border Partnership Strategies                            

               13.3. Global Supply Chain Dynamics                       

               13.4. Case Studies: Success and Failure in Global Markets                             

               13.5. Strategies for Global Expansion and Localization                     

                                            

14. Company Profiles                                   

               14.1. Pfizer Inc.                

               14.2. Novartis AG                           

               14.3. Sanofi                      

               14.4. Bristol Myers Squibb                          

               14.5. Agios Pharmaceuticals                       

               14.6. Abbvie                     

               14.7. Astellas Pharma                   

               14.8. Daiichi Sankyo                      

               14.9. Incyte Corporation                              

               14.10. Cardiff Oncology                 

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.